PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Molecular and Clinical Pharmacology, Materials Innovation Factory, University of Liverpool, Liverpool, UK.\', \'Department of Chemistry, University of Liverpool, Liverpool, UK.\', \'Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK.\', \'Pat Bray Electrical, Wigan, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/cpt.1909
?:doi
?:hasPublicationType
?:journal
  • Clinical pharmacology and therapeutics
is ?:pmid of
?:pmid
?:pmid
  • 32438446
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.699
?:rankingScore_hIndex
  • 169
is ?:relation_isRelatedTo_publication of
?:title
  • Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32438446>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32438446>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all